To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to assess safety and tolerablility of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of metformin.

Key facts

Study ID

NCT00774553

Run by

AstraZeneca

People needed

70

Starts

2008-10-01

Expected to finish

2010-01-01

Last updated by the study team

2010-01-15

Who can join

Age: 30 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female (with non child-bearing potential)
• Diagnosed diabetes Mellitus patients treated with metformin alone or one other anti-diabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start.t
• HbA1c <11 % at screening (HbA1c value according to international DCCT standard)

You may not qualify if…

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP
• History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease
• Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.

Where it is running

• Research Site — San Antonio, Texas, United States
• Research site — Ahmedabad, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.